


# Research Transparency Panel Meeting Summary

**Roche**

30th November 2023

15:00–16:00



# Data Access Proposal Request

## Flatiron Health UK RWD Products

- Non Small Cell Lung Cancer
- Breast Cancer
- Prostate Cancer
- Multiple Myeloma
- Chronic Lymphocytic Leukaemia
- Diffuse Large Cell Lymphoma

## Attendees

### FLATIRON HEALTH UK

- Adam Manhi (chair)
- Liv Bryan (programme manager)

### RESEARCH TRANSPARENCY PANEL

- Jennifer McCaffery (lay)
- Kaeden Bunting (lay)
- Thomas Smith (patient)
- Sonia Patton (patient)
- Yanrong Jiang (clinical)

## Conflicts of interest

No conflicts declared by panel

## Decision outcome

Approved

## Summary of discussion

- Comprehensive lay summary using understandable, plain language
- Broad number of use cases selected and evidenced to demonstrate patient benefit
- A concise summary of analytics approaches and rationale by use case highlighted
- Research benefits clearly outlined for patients, but also for the UK healthcare ecosystem (e.g. cost-effectiveness assessment)
- The panel raised several comments on other aspects of the application including:
  - Specific examples of the current unmet needs across tumour types would have been helpful

- Content and language was lengthy at points and could benefit from being more concise
- More clarity needed around the potential impact of RWD insights on specific patient cohorts and their treatments/outcomes
- Inclusion of examples of target outputs (e.g. conferences like ESMO) where insights will be shared further
- Full completion of the form required (i.e. the applicant had missed a verification step in the form inadvertently)